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Abstract: Alzheimer’s disease (AD) is progressive neurodegenerative disorder characterized by brain
accumulation of the amyloid β peptide (Aβ), which form senile plaques, neurofibrillary tangles (NFT)
and, eventually, neurodegeneration and cognitive impairment. Interestingly, epidemiological studies
have described a relationship between type 2 diabetes mellitus (T2DM) and this pathology, being
one of the risk factors for the development of AD pathogenesis. Information as it is, it would point
out that, impairment in insulin signalling and glucose metabolism, in central as well as peripheral
systems, would be one of the reasons for the cognitive decline. Brain insulin resistance, also known
as Type 3 diabetes, leads to the increase of Aβ production and TAU phosphorylation, mitochondrial
dysfunction, oxidative stress, protein misfolding, and cognitive impairment, which are all hallmarks
of AD. Moreover, given the complexity of interlocking mechanisms found in late onset AD (LOAD)
pathogenesis, more data is being obtained. Recent evidence showed that Aβ42 generated in the brain
would impact negatively on the hypothalamus, accelerating the “peripheral” symptomatology of
AD. In this situation, Aβ42 production would induce hypothalamic dysfunction that would favour
peripheral hyperglycaemia due to down regulation of the liver insulin receptor. The objective of this
review is to discuss the existing evidence supporting the concept that brain insulin resistance and
altered glucose metabolism play an important role in pathogenesis of LOAD. Furthermore, we discuss
AD treatment approaches targeting insulin signalling using anti-diabetic drugs and mTOR inhibitors.
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1. Introduction
Prevention is a key factor when trying to reduce the impact of age-related diseases like cardiovascular
alterations, cancer and dementias. These pathologies do not only create substantial personal and family
burdens but, unsustainable increases in the public health economic costs in developed populations.
The most common form of dementia is Alzheimer’s disease (AD) [1–7]. The number of patients
diagnosed with AD is rapidly increasing worldwide and becoming a common cause of death in aging
populations [4–7]. Moreover, no effective treatments have been established yet to prevent or delay the
progression of AD [8,9].
AD has been classified into two groups, depending on its onset: the first classification is familial
AD, related to genetic alterations of the amyloid beta precursor protein (AβPP) and preselinins
(PS1) [1–5]. This subgroup represents approximately about 3% of the diseased patients [1,4]. The other
classification group is the late onset form (LOAD), also known as sporadic. It accounts for the remaining
97% of diagnoses [1,4]. Historically, the neuropathological characteristics of AD were described
through the amyloidogenic hypothesis by Selkoe (1992) [9,10]. They were: cognitive loss, abnormal
accumulations of Aβ and hyperphosphorylation of TAU protein in areas of the cerebral cortex and
hippocampus [6–10]. Initially, the Aβ peptide is generated from the catabolism of AβPP, a plasmatic
membrane protein with a single domain found in different cellular types, including neurons, astrocytes
and oligodendrocytes [10,11]. This protein is cleaved by α-, β-, and γ-secretase enzymes, as well as,
a complex of proteins containing presenilin 1 (PS1) [4,10,11]. In neuropathological situations, AβPP
is metabolized predominantly by the amyloidogenic pathway in which the Aβ cleaving enzyme
1 (BACE 1; β-secretase) breaks AβPP by the N-terminal end while γ-secretases cleave the C-terminal
end, obtaining Aβ40 and Aβ42 fragments that remain in the extracellular space [4,10].
Since the presence of amyloid plaques has been repeatedly demonstrated not to be strictly
correlated with AD symptoms, considerable research has focused on understanding its actual role.
Now, one of the working hypotheses is that Aβ42 accumulates in the form of several soluble species,
oligomers and protofibres, which contain potentially high toxic properties [11]. As the concentration of
these molecules increases, they continue to aggregate into insoluble fibres that are the main constituents
of Aβ plaques. Nevertheless, some authors suggest that the cognitive impairment correlates best with
alterations on the TAU protein than the Aβ plaques, suggesting a predominant role for TAU in the
pathogenesis of AD [4,9–11]. Therefore, in the field of AD research, there are multiple approaches to
consider when trying to understand the origin of this disease.
Another hallmark that has been associated as a risk factor for LOAD is the ε4 allele of the
apolipoprotein E (APOE) gene [12–16]. This information was demonstrated when studying how the
response to intranasal insulin differed between carriers of different apolipoprotein ε4 alleles [14]. APOE
genotype influences peripheral glucose and insulin metabolism. Also, as it occurs in other diseases,
gender has an influence in the affection and incidence of pathology. APOE positive carrier women have
higher risk than men to develop LOAD and, respond less favourably to insulin related therapies [13–16].
Importantly, the molecular basis of this association has remained elusive for decades. Yet, recent
findings determined that APOE4 interacts with insulin receptors (IR), impairing its trafficking between
endosomes and the plasmatic membranes, by trapping them and favouring the development of
impaired insulin signalling [16]. Furthermore, the association between T2DM and LOAD amyloid
pathology is specific among carriers of the apolipoprotein E (APOE) ε4 gene allele, compared to
the common ε3 allele and the protective ε2 allele [16]. All these new data reinforce the metabolic
hypothesis that T2DM appears as a key factor involved in LOAD [17–20].
Currently, only symptomatic therapies are available and their effects are modest
(acetylcholinesterase inhibitors and NMDA antagonists) [8]. Memantine (MEM), a low-affinity voltage-
dependent uncompetitive antagonist of NMDA receptors (NMDAR), is currently being prescribed
for the treatment of AD, jointly with acetylcholinesterase inhibitors such as galantamine, donepezil,
and rivastigmine [20–22]. Since it is a low-affinity antagonist, it blocks the NMDAR but it is rapidly
displaced from it, avoiding prolonged receptor blockade and the associated negative side effects on
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learning and memory that have been observed in high affinity NMDAR antagonists. Unfortunately,
and despite its high prevalence and mortality, there are no effective disease-modifying therapies
at present.
For the last 25 years, the main focus of research has been on senile plaques, considering them
the main source of the symptoms of AD. Consequently, therapeutic approaches have focused on
this biomarker. Recent studies at preclinical level and in LOAD patients show that an antibody
(aducanumab) penetrates in the brain and reduces soluble and insoluble Aβ42 in a dose-dependent
manner [23]. In patients with mild LOAD, a year of treatment by administering monthly intravenous
infusions of aducanumab, reduces cerebral Aβ and patients show cognitive improvements. These
results suggest that the amyloidogenic hypothesis may contribute to the development of LOAD
exacerbating its consequences, possibly along with other factors such as metabolic alterations, glia
activation, mitochondrial alteration and oxidative stress, among others [23]. Thus, the classical
definition of AD that attributes the main role to plaques and tangles as the main responsible source of
the neuropathophysiology should be modified.
Accordingly, the main objective of this review is to summarize the information regarding metabolic
alterations and the appearance of LOAD, especially associated with type II diabetes mellitus (T2DM).
Finally, the pathways associated with the IR signalling and its inhibition will be presented. Our aim
is to evaluate the possible application of drugs involved in the regulation/modulation of brain IR in
LOAD treatment, in order to improve cognitive performance and deter the development of AD.
2. The Hippocampal Insulin Receptor Is a Key Target in Physiological Cognitive Processes
and Neurodegeneration
In 1985, previous to the establishment of the amyloidogenic hypothesis as the paradigm for the
study of AD, Hoyer, proposed the concept of central insulin resistance and dysfunctional insulin
signalling in LOAD (Table 1) [24–28]. Insulin resistance is defined as a situation in the human organism
in which it does not respond sufficiently to the physiological levels of insulin [29–39]. It is involved
in the onset of the metabolic syndrome. Yet, even though this idea had already been theorized,
these conclusions did not begin to be established until the publication of the Rotterdam study, a
clinical report that described the connection between T2DM and LOAD, revealing that those patients
that had been diagnosed with diabetes had higher risk of dementia [33,34]. Subsequent clinical and
epidemiological studies have confirmed this potential association demonstrating that the alteration of
metabolic parameters, such as hyperglycaemia and hyperinsulinemia, correlates positively with the
development of pathology related to LOAD, mainly with the cognitive loss [35–41].
Table 1. Examples of IR signalling pathway alterations in the brain in late onset Alzheimer’s disease.
Reference Physiological Alterations Pathological Effects
Biessels and Reagan, 2015 [36]
Down regulation in neurogenesis were associated
with reductions in dendritic spine density in CA1
pyramidal neurons.
Learning and memory loss.
Hoyer, S., 2004 [26]
Decline in ATP levels (mitochondrial alteration).
PKB activity inhibition
GSK3 activity increase.
Amount in TAU phosphorylation.
Oxidative stress increases
De Felice, F.G., 2014 [29]
Neuroinflammation and TNFα increase
associated with neuronal ER stress and JNK
activation
Brain IR down regulation and
synaptic alteration.
Grillo, C.A., 2015 [42]
Hippocampal-specific insulin resistance
using a lentiviral vector expressing an IR
antisense sequence
Down regulation of GluN2B and
GluA1 phosphorylation at synapses.
Memory failure independent of
peripheral metabolic alterations.
Hoyer, S., 1994 [28] Insulin modulates levels of acetylcholine andnorepinephrine neurotransmitters, Cognition loss
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Table 1. Cont.
Reference Physiological Alterations Pathological Effects
Frolich, L.D., 1999 [25] Formation and deposition of advanced glycationend products (AGEs)
Up-regulate APP via oxidative stress
and Aβ production enhancement
De Felice and Ferreira, 2014 [30] mTOR dysregulation Learning and memory deficits, cellcycle reentry
Craft, S. 2012 [6] Insulin resistance increases vascular dysfunction Vascular dementia
Craft, S. 2005 [43] Insulin resistance inhibits IDE activity Aβ levels Increase
Under physiological conditions when insulin binds to the IR, a cascade regulates key downstream
serine/threonine kinases such as, protein kinases B (AKT/PKB), mechanistic target of rapamycin (mTOR),
and extracellular signal-regulated kinases (ERK), that eventually phosphorylate serine/threonine
residues of the insulin receptor substrates (IRS), inhibiting insulin signalling in a negative feedback
regulation (Figure 1) [35–41,44–46]. In neurons, the phosphoinositide 3-kinase (PI3K), AKT, glycogen
synthase kinase 3β (GSK3β), BCL-2 agonist of cell death (BAD), fork-head box (FOX), mTOR and the
mitogen activated protein kinase (MAPK) pathways are critical for cell survival signalling and are
regulated by the activity of the IR [43,47,48]. Therefore, alteration of the physiological activity on these
pathways might be the source of alteration in normal neuronal performance, supporting the hypothesis
that brain insulin resistance could promote LOAD, precisely by inhibition of these pathways [39,41,45].
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the mitochondria, generating free oxygen radicals that modulate APP and JNK. 
Figure 1. Consequences of insulin and Aβ interactions on reduced neuronal IR signalling. In type 2
diabetes, there can be decreased or increased levels of insulin in brain, along with IR desensitization.
Soluble Aβ oligomers block IR. Increased Aβ levels will compete for insulin degrading enzyme
(IDE) against cerebral insulin. Reduced IR signalling results in downstream negative effects on PI3K
activity and proteins like PKB/AKT. Consequences of this include: reduced glucose metabolism
and increased oxidative stress which modulate APP and JNK activity. Moreover, reduced GSK3β
phosphorylation leads to up-regulation in TAU phosphorylation and Aβ formation. Likewise, Aβ
promotes the activation of microglia increasing the levels of cytokines, mainly TNFα that activates JNK
that subsequently inhibits the brain IR. On the other hand, Aβ can alter the endoplasmic reticulum and
the mitochondria, generating free oxygen radicals that modulate APP and JNK.
The metabolic hypothesis associated with the appearance of LOAD is based on the fact that
cerebral IRs are widely distributed in the brain, existing in higher densities in the olfactory bulb,
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hypothalamus, cerebral cortex and hippocampus [28,49]. Frölich and colleagues reported a significant
reduced level of CNS IRs in LOAD patients [24–28]. Research from the group led by de la Monte,
demonstrated significant decreases in insulin and insulin growth factor (IGF-I) receptor levels in LOAD
frontal cortex, hippocampus, and hypothalamus of AD patients [45,50]. In addition, the same research
group correlated the decrease in gene expression and protein levels of insulin, IGF1 receptors and other
downstream molecules, with impaired acetylcholine production and cognitive performance in LOAD
brains. Another recent study strengthened this hypothesis by demonstrating significant alterations in
mRNA expression profiles of genes related to insulin signalling in the cortex and hippocampus [51].
Intriguingly, the highest differences in mRNA expression were detected in the hippocampal region of
the brain, the main area associated with the cognitive process [51].
A recently published work by the group of Butterfield, reported new information about the
complexity of LOAD [44]. In essence, they suggested that human and preclinical studies have provided
convincing evidence that in the brains of many LOAD patients and rodents there is a decrease in
energy metabolism and, in particular, a decrease in glucose utilization. As a consequence, that LOAD
will represent a metabolic disease in which brain glucose utilization and energy production are
altered is gaining attention [24–28,39]. Additional data by Grillo and co-workers reported in a very
interesting study, that insulin resistance in the hippocampus would prevent the correct structuring of
memory, which would be directly related to cognitive loss [42,52]. The administration of a lentiviral
vector expressing an antisense sequence of the brain IRs to rats caused for cognitive loss. Using
this experimental approach, the authors were able to decrease the number of IR in the hippocampus
without affecting peripheral glucose homeostasis, thus generating a specific rat model of altered brain
insulin signalling in the hippocampus [42]. This study demonstrated that insulin resistance in the
hippocampus might induce a neuroplasticity deficit, including deficits in spatial learning and memory.
In addition, the hippocampal levels of the phosphorylated GluN2B and GluA1 subunits were reduced,
providing a possible molecular evidence on how the deficit in synaptic transmission occurs when there
are alterations on the insulin signalling in the hippocampus [52].
Concurrently, the de Felice research group has demonstrated that Aβ oligomers bind to IR,
causing for their removal from the neuronal surface membrane, causing its cellular internalization
and, thereby providing an evidence for brain insulin resistance in LOAD [19,29]. In addition, some
authors have reported that insulin prevents detrimental effects of Aβ oligomers on the inactivation of
brain IR [53]. Furthermore, insulin promotes the release of intracellular synaptic Aβ, and regulates
expression of insulin-degrading enzyme (IDE), a protease involved in clearance of Aβ (Table 1) [17].
A possible conclusion from the outcome of these studies might suggest that the presence of Aβ
peptide may not be the only factor necessary for cognitive loss. However, Aβ paired with a process of
obesity and hence, peripheral and central insulin resistance, may exacerbate the onset of LOAD and
worsen cognitive loss. Then, LOAD should be considered globally as a brain expression of a metabolic
disease of the whole organism, and correspondingly should not focus only on events that occur in the
brain [32].
3. Molecular Bases of Insulin Receptor Modulation
Insulin is a peptide hormone of 5.8 KDa that is synthesized and secreted by the pancreatic β cells.
Once released to the blood vessels, insulin is transported to the brain through the blood brain barrier
(BBB) and binds to their cognate receptors [24,25]. The IR is a glycoprotein consisting of an extracellular
α subunit (135 KDa) that inhibits the activity of the β-transmembrane subunit (95 KDa) [26–28]. The IRs
belongs to the tyrosine kinase receptor superfamily. When insulin binds to the α subunit, it dimerizes
to form the α2β2 complex in the cell membrane, it leads to autophosphorylation of the beta subunit on
Tyr1158, Tyr1162, and Tyr1163, which constitutes the first step in IR activation.
It has been shown that the activation of the IR tyrosine kinase, leads to the recruitment and
phosphorylation of several substrates, including IRS1-4, the adapter protein SHC, growth factor
receptor-bound protein-2 (Grb-2 or GAB1), dedicator of cytokinesis (DOCK1), casitas B-lineage
Pharmaceuticals 2018, 11, 11 6 of 16
lymphoma (CBL) and an interacting protein called APS which are associated proteins, all of which
provide specific binding sites for the recruitment of other proteins of the signalling cascade [49].
These phospho-tyrosine residues bind to IRS 1 and 2 in order to initiate several signalling pathways,
including the PI3K-AKT pathway [54,55]. PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2)
to phosphatidylinositol-3,4,5-trisphosphate (PIP3). This conversion favours the activation of the
PKB/AKT through the 3-phosphoinositide dependent kinase (PDK). PIP3 recruits AKT to the plasma
membrane, where it becomes phosphorylated by 3-phosphoinositide-dependent protein kinase 1
(PDK1), which regulates the translocation of glucose transporter type 4 (GLUT4) to the plasma
membrane in the hippocampus.
In the brain, IR activation promotes neuronal survival through the phosphorylation of the FOXO
transcription factor, favouring its way out of the nucleus of the cell [55–58]. FOXO is a transcription
factor involved in the expression of pro-apoptotic mediators, thus contributing to the process of cell
death. All this processes that are regulated by the signalling of the IR, result in deleterious effects on
synaptic function and cognitive impairment. The activation of IR tyrosine kinase also results in the
activation of the RAS/MAPKs pathway. The stress activated protein kinases (SAPK) or MAPK, include
extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), p38 and the c-Jun-N-terminal kinases
(JNKs) [56]. The JNK family is made up by 3 genes that codify for 10 different products classified
into 3 different isoforms: JNK1 (Mapk8), JNK2 (Mapk9) and JNK3 (Mapk10) and while JNK1 and JNK2
are ubiquitously expressed, JNK3 expression is principally restricted to regions of the brain, heart
and testis. When activated, the JNK1 phosphorylates IRS-1 in the serine residues (IRS-1pSer) [29].
This alteration blocks the signalling of the insulin pathway and favours peripheral resistance to this
hormone. Based on this activation sequence, JNK1 appears as a key protein to investigate novel
therapeutic targets that prevent the development T2DM [54,56,58].
4. Relationship between Insulin Receptor Activation and TAU Phosphorylation
Recent studies have suggested a potential link between impaired insulin signalling and
pathogenic alterations of TAU. As we stated before, the activation of IR, IRS1 and 2 initiates several
signalling pathways, including the conversion of PIP2 into PIP3, which favours the activation of
PKB/AKT and, consequently, leads to the translocation of GLUT4 to the plasma membrane [56,59–62].
Concurrently, AKT signalling affects other diverse cellular responses, like neuronal survival and TAU
phosphorylation. Other important targets such as the GSK3β are also regulated by AKT, inhibiting
its activation by phosphorylation. Insulin resistance reinforces the activation of GSK3β leading to
increased phosphorylation levels of TAU protein and, the subsequent formation of neurofibrillary
tangles, one of the hallmarks of AD neuropathology [59–62]. Schubert and co-workers investigate the
biochemical processes associated with neurodegeneration in a brain specific IR knockout (NIRKO)
mice model [63]. They reported that NIRKO mice presented decreased AKT activity thus, having the
previously mentioned increases in GSK3β activation and TAU hyperphosphorylation at specific sites
associated with LOAD. This data, along with other being produced in the same line on the study of
metabolic alterations, confirm how altered insulin signalling in the brain leads to the appearance of
classical hallmarks of LOAD and, demonstrates, how neuronal insulin resistance predisposes for the
appearance of pathologies. Freude and co-workers reported that brain insulin receptor specifically
modulates TAU phosphorylation at Ser202, a key site which predisposes for tangle formation after
peripheral insulin injection in mice [64]. The effects of injected insulin on TAU were abolished in the
NIRKO mice.
Studies performed in post-mortem brains from patients with tauopathies including AD, Pick’s
disease, corticobasal degeneration, and progressive supranuclear palsy, showed increases in
phosphorylated IRS1 levels which, as we have already mentioned, is a specific marker of insulin
resistance. Interestingly, two independent research groups published their research on alterations
in brain insulin receptors and downstream pathway in LOAD. Liu and colleagues reported that the
insulin-signalling pathway is decreased in LOAD brain and demonstrated that alteration in insulin
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signaling may contribute to LOAD through the hyperphosphorylation of TAU [59]. In addition,
authors suggest that brain insulin resistance is also correlated with calpain activation, a protease
involved in cyclin-dependent kinase (CDK5) activation, a kinase involved in the phosphorylation of
TAU [35]. Similar results were reported by other authors:
• Talbot and co-workers reported that LOAD patients show impaired brain insulin-signaling
transduction with reduced tyrosine kinase activity of the IR [35]. IR and its receptor analogous
IGF1R form heterodimers (IR/IGF1R) that modulate the selectivity and affinity for insulin and
IGF1 in the activation of signaling molecules [65].
• Yarchoan and co-workers reported an increase in serine phosphorylation of IRS1 (inactivation),
the phosphorylation of IRS1 on multiple serine residues can inhibit IRS1 activity, leading to insulin
resistance in the hippocampus in LOAD and other tauopathies [54].
Finally, recent data reported that insulin accumulates intraneuronally together with
hyperphosphorylated TAU in LOAD and several other tauopathies suggesting that hyperphosphorylated
TAU-bearing neurons is a causative factor involved in the brain insulin resistance observed in LOAD
(Table 1) [66].
5. Role of the Glucose Transporter 4 in Cognition
Glucose transporter 4 (GLUT4) is found in peripheral tissues like the skeletal muscle, heart,
and adipose tissue [67–69]. Its role in the physiology of the cell is mainly the transport from the
extracellular space into the citosol for its metabolism. Thus, in response to the activation of the IR
signaling cascade by insulin, GLUT4 is translocated to the plasma membrane to facilitate glucose entry
into the cell. Moreover, GLUT4 is found in brain regions such as the cerebellum, and especially the
hippocampus. At the hippocampal level, the cognitive improvement effects related to insulin may occur
via upregulation in GLUT4-mediated glucose uptake [68]. Thus hippocampal GLUT4 overexpression
could be a target to improve the cognitive process in AD. This could be the case of quercetin which
improves cognitive dysfunction mediated by chronic unpredicted stress, through upregulation of
GLUT4 expression in the hippocampus [69].
6. Effects of Aβ Oligomers on Brain Insulin and Peripheral Metabolic Tissues
Recent hypothesis suggests that since diabetes increases both Aβ production and TAU
phosphorylation, both T2DM and Aβmay cooperate to induce neurodegeneration in LOAD [70,71].
It has been pointed out that soluble Aβ peptide oligomers would act as synaptotoxins [10–12].
Moreover, since Aβ and insulin are both amyloidogenic peptides sharing a common sequence
recognition motif, it is possible that both molecules are able to bind to the IR. Given this assumption,
Aβ may also potentiate insulin resistance through antagonistic effects, blocking the downstream
pathway and facilitating the phosphorylation of GSK3β. Thus, the aging process associated with
insulin resistance, jointly with Aβ production and hyperphosphorylation of TAU, can have a synergic
effect leading to neuronal dysfunction.
In addition to the effects of Aβ oligomers on TAU phosphorylation, a recent study using a mice
model of AD, reported peripheral metabolic changes in plasma and liver extracts [72]. Also, Zhang
and co-workers demonstrated in APPswe/PS1E9 mice that the Aβ42 peptide induces hepatic insulin
resistance in vivo through the activation of the Janus Kinase 2 (JAK2), suggesting that inhibition of
Aβ42 peptide production in the brain may be a novel strategy for the treatment of insulin resistance
and therefore T2DM [73–75].
As, an overview, we can state that LOAD has a multifactorial component and should be
addressed as a disease affecting the whole organism [70,71]. Moreover, preclinical studies in rodents
have established that the oligomers of Aβ administered directly to hippocampal neurons induce
synaptic loss and neuronal dysfunction, which eventually leads to memory loss [11]. Likewise,
intracerebroventricular (icv) administration of Aβ oligomers causes behavioral changes and AD-like
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pathology in primates, providing an excellent model for investigating AD-related mechanisms [72].
Furthermore, Clarke and co-workers reported that intracerebral injected Aβ causes peripheral glucose
intolerance and insulin resistance, as well as, inflammatory processes in the hypothalamus and adipose
tissue, along with alterations of GLUT-4 insulin-induced cell membrane translocation in skeletal
muscle [76].
Accordingly, Aβ peptides generated in the brain reach the hypothalamus and alter the body’s
energy balance, favouring the apparition of a T2DM. In this line, Arietta-Cruz et al. demonstrated an
increase in plasma glucose levels when injecting β25-35 into the hypothalamus of rat as a consequence
of enhanced hepatic glucose production [77,78].
In addition, generated brain Aβ could accumulate in peripheral tissues such as the pancreas
and skeletal muscle contributing to the negative effect on peripheral glucose metabolism [79]. Thus,
when trying to explain this complicated bidirectional process between LOAD and T2DM, recent
reported data suggests the existence of something called Factor X, a molecule or pathway that would
be the bridge between Aβ as responsible of LOAD and T2DM. In addition, authors suggest that
characterization of Factor X will be important in order to the development of a potential therapeutic
target for LOAD prevention [70].
7. Is BACE1 a Potential Bridge between Aβ and T2DM?
BACE1 is involved in LOAD as the enzyme responsible for the rate-limiting step in Aβ production
through the cleaving of the amyloid precursor protein (APP). It has been demonstrated that monomers
of Aβ1-42 augment BACE1 gene transcription activation through the MAPK8/JNK1-MAPK9/JNK2
signalling pathway and by interfering with its lysosomal degradation leading to an amyloid vicious
cycle [80–82].
Interestingly, recent data demonstrated at the preclinical level that neuronal expression of human
BACE1 causes systemic diabetic complications via the induction of hypothalamic impairment, insulin
resistance, hepatic deficits and global glucose alterations [79,80]. Using the PLB4 mouse it was
demonstrated that the risk of diabetes when BACE1 is overexpressed in neurons increases, providing
for a complex mechanistic interaction between T2DM and LOAD. Human (h) BACE1 neurogenic
knockout has recently been shown to induce Aβ accumulation, promotes brain inflammation and
generates LOAD-like phenotypes in mice in the absence of expression of mutant APP, suggesting that
BACE1 represents a molecular risk factor for AD related to the aging process [83].
Plucińskaí and colleagues showed that the overexpression in neurons of the amyloidogenic
enzyme, BACE1, is sufficient to increase the risk of developing T2DM [80]. Therefore, this study
demonstrates that neuronal BACE1 causes metabolic dysregulation throughout the body along with
brain inflammation and cognitive impairment related to the process of amyloidosis. The PLB4 mouse
presents a diabetic profile, thus demonstrating that neuronal BACE1 is in part responsible for the
appearance of these peripheral metabolic alterations [84].
Therefore, even though the hypothesis states that diabetic complications promote the onset
and or progression of AD, the reverse scenario may also apply. This is also in agreement with the
potential hypothesis that hyperglycaemia can also originate in the brain and affect the rest of the body
(Figure 2). Meakin and colleagues demonstrated that knockout mice for BACE1−/− are thin, resistant
to obesity induced by high fat diet and show an increase in insulin sensitivity in peripheral tissues
with a regulation of improved glucose metabolism throughout the body [85]. These results outline a
novel aspect of BACE1 function in the regulation of metabolic homeostasis and, provide a possible
connection between T2DM and AD [85].
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of the drug reversing the damage that neuroinflammation causes in the structural plasticity of the
dendrites. Thus, it has been observed that treatment with pioglitazone can reverse the loss of synaptic
density induced by Aβ peptide generation [91]. Although preclinical data gives support to the potential
beneficial effects of pioglitazone in AD, clinical data reported until now shows conflicting results
regarding efficacy due to the many limitations of these trials [100,101]. Therefore, further clinical
trials on the potential use of pioglitazone for the treatment of LOAD are necessary. Phase II clinical
trials of the drug demonstrate that it is a safe and well tolerated molecule. Two Phase III trials are
currently under way, of which conclusions regarding their effectiveness against AD cannot yet be
obtained [91,100,101].
8.2. Intranasal Insulin for LOAD Treatment
In previous preclinical studies, intranasal treatments with insulin or insulin analogues have
afforded some degree of memory improvement or of protection against cognitive deterioration in mice
models of AD [101–109]. However, in a recent reported study (NCT01595646), Craft and co-workers
reported that intranasal-administered insulin improves memory for adults with mild cognitive
impairment and LOAD [108–110]. Furthermore, authors suggest that insulin could improve and
modify the AD-related pathophysiologic processes. Another interesting point is that the therapeutic
effects of insulin are modulated by APOE genotype. Accordingly, the study gives support to the
continued investigation on potential stimulation of insulin receptor as a therapy for LOAD [108].
8.3. Rapalogs
It is well known that the PI3K/AKT/mTOR dysregulation may decrease the autophagic process
leading to the accumulation of Aβ42 deposition and protein aggregation [44]. Likewise, mTOR is
involved in the modulation of IRS1 activity, representing one of the best-characterized events leading to
insulin resistance [44]. Therefore, alteration or better activation of the mTOR pathway could represent
an important link between Aβ and insulin signalling, providing new insights into the relationship
between insulin resistance and incidence of AD.
mTOR is a kinase involved in energy and protein homeostasis in cells. Both rapamycin and its
derivatives prevent the formation of the mTORC1 complex, acting as allosteric inhibitors [109–111].
However, the main limitations of rapamycin are its solubility, long half-life and the poor oral absorption
making it necessary for the development of analog molecules, among them temsirolimus, which is
an ester derived from rapamycin, soluble in water and suitable for administration both oral and
intravenously. Its use was approved in 1977 by the FDA and the European Medicines Agency for
the treatment of renal carcinoma [111]. Both drugs have the same mechanism of action. Jiang and
co-workers recently reported that temsirolimus promotes autophagic clearance of Aβ, exerts protective
effects accompanied by an improvement in spatial cognitive functions in APP/PS1 model of familial
AD [102]. This study give support to the therapeutic potentials of temsirolimus in preclinical models
of AD.
9. Conclusions
Given the amount of data of which we are in possession now, it can be concluded that the
pathology hereby described as LOAD is very closely related to the alterations derived of insulin
resistance. Effective energy metabolism is the base on the proper functioning of cellular types and,
when disrupted, affects negatively their function. In the case of neurons, which are having glucose as
its main energy source, this situation can be utterly disastrous leading to their ineffective activity and
consequently cognitive decline. That is why the IR has such a prominent role.
It is now well established Aβ could bind to the IR in the hippocampus, revealing important
cognitive loss, when the receptor is inhibited and enhancing the neurodegenerative process in this
brain region. Moreover, Aβ bind to the liver IR in the preclinical APPswe/PS1E9 mice model of
familial AD, suggesting the possibility that decreases of Aβ production may be a novel potential
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treatment for use in T2DM (Figure 2) [73,74,112]. Lastly, the therapeutic potential of Aβ inhibitors
(for example BACE 1 inhibitors) has not yet been verified in clinical trials. However, antidiabetic
therapies such as pioglitazone or intranasal insulin are more likely to be effective in individuals with
LOAD. Therefore, we suggest that the future timing of a more effective LOAD therapy should be the
key factor in determining if T2DM drugs shown beneficial actions in LOAD. Targeting the early stages
of LOAD, before widespread cognitive loss due to synapses and neurons degeneration has occurred
is likely to produce the best clinical outcome, but identification of individuals at this stage of LOAD
is difficult. Accordingly, the modulation of brain IR preventing its inactivation could be a suitable
strategy in a combinatory strategy therapy for LOAD.
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